louisiana glp-1 intestinal paralysis law office Ozempic Lawyer Louisiana Patients Are Losing Coverage
Description
China is Next Big Market: Manufacturing Challenges, Supply Shortages
Free consults.
The lawmakers proposal comes at a time when state health officials are advocating to []
In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk
